Derma Sciences' diabetic foot ulcers drug trial meets primary endpoint
Derma Sciences, Inc. a medical device and pharmaceutical company focused on advanced wound care, announced positive results from its phase II clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100 percent epithelialized with no drainage, as well as all secondary endpoints measured at this time. DSC127 is a patented, topically applied novel angiotensin analogue that targets receptors that are up-regulated upon injury to tissue.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063